Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin.
Proconvulsive tendency of imipenem/cilastatin is one of its well-known side effects. Most studies report incidence rates ranging from 1.5 to 3%. There is no study on the incidence rate among children with systemic malignancies. Eighty-two patients with various malignancies who received imipenem/cilastatin 143 times for neutropenic fever between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified. Three of these patients had convulsions attributed to imipenem/cilastatin; 3.6% of the patients had seizure, or 2% of imipenem/cilastatin administrations was followed by a seizure attack.
Karadeniz
C
C
Department of Pediatric Oncology, Gazi University, Faculty of Medicine, Beşevler, Ankara, Turkey. ceydak@med.gazi.edu.tr
Oğuz
A
A
Canter
B
B
Serdaroğlu
A
A
D000293:Adolescent; D002648:Child; D015377:Cilastatin / Q000009:adverse effects* / Q000627:therapeutic use; D000077728:Cilastatin, Imipenem Drug Combination; D004338:Drug Combinations; D005260:Female; D005334:Fever / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D015378:Imipenem / Q000009:adverse effects* / Q000627:therapeutic use; D009369:Neoplasms / Q000150:complications*; D009503:Neutropenia / Q000150:complications; D011480:Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012640:Seizures / Q000139:chemically induced*; D013845:Thienamycins / Q000009:adverse effects* / Q000627:therapeutic use
D004338:Drug Combinations; D011480:Protease Inhibitors; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem; D000077728:Cilastatin, Imipenem Drug Combination